You are currently viewing Ciloa at the Obesity & Weight Loss Drug Development Summit Europe
  • Robert Mamoun, Co-founder & CEO of Ciloa, will take part in the 2nd Obesity & Weight Loss Drug Development Summit Europe on 28–29 October 2026 in Munich. He will join the Industry Leaders’ Fireside Chat and present “A Biomimetic Adiponectin–Extracellular Vesicle (APN-EV) Combined with GLP-1: Efficacy in Preclinic.” The talk will show how APN-EV restores functional adiponectin signalling outside the incretin pathway to complement GLP-1 therapies, supporting insulin sensitivity, tolerability and muscle preservation.
  • Attending the summit? Contact us to meet in Munich.